475085-56-4

Basic information

• Product Name: 1-Piperidinecarboxylic acid, 4-(4-chlorophenyl)-4-hydroxy-3,3-dimethyl-, 1,1-dimethylethyl ester
• CAS NO: 475085-56-4
• Molecular Formula: C18H26ClNO3
• Molecular Weight: 339.862
• Mol File: 475085-56-4.mol

Chemical Properties

• CAS DataBase Reference: 1-Piperidinecarboxylic acid, 4-(4-chlorophenyl)-4-hydroxy-3,3-dimethyl-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylic acid, 4-(4-chlorophenyl)-4-hydroxy-3,3-dimethyl-, 1,1-dimethylethyl ester(475085-56-4)
• EPA Substance Registry System: 1-Piperidinecarboxylic acid, 4-(4-chlorophenyl)-4-hydroxy-3,3-dimethyl-, 1,1-dimethylethyl ester(475085-56-4)

Safety Data

• Hazardous Substances Data: 475085-56-4(Hazardous Substances Data)

Upstream product

• 873-77-8 (4-chlorphenyl)magnesium bromide 
• 324769-06-4 tert-butyl 3,3-dimethyl-4-oxopiperidine-1-carboxylate 
• 106-39-8 bromochlorobenzene 
• 173186-91-9 N-benzyl-3,3-dimethylpiperidine-4-one 
• 34737-89-8 1-Benzyl-3-methyl-4-piperidon 

Downstream Products

• 690660-25-4 R-4-(4-chloro-phenyl)-3,3-dimethyl-piperidin-4-ol 
• 690660-23-2 S-1-(5-{3-[4-(4-chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-ethanone 
• 946585-25-7 N-((R)-1-((S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl)-3-methyl-1-oxobutan-2-yl)-3-sulfamoylbenzamide 
• 946593-91-5 C₃₂H₃₇ClN₄O₄ 
• 946592-68-3 N-((R)-1-((S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl)-3-methyl-1-oxobutan-2-yl)-3-hydroxy-3-methylbutanamide 
• 946590-21-2 C₂₃H₃₃ClN₂O₃ 
• 946587-15-1 (1R,3S)-N-((R)-1-((S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl)-3-methyl-1-oxobutan-2-yl)-3-hydroxycyclopentanecarboxamide 
• 946587-14-0 (1S,3R)-N-((R)-1-((S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl)-3-methyl-1-oxobutan-2-yl)-3-hydroxycyclopentanecarboxamide 
• 946587-13-9 (1S,3S)-N-((R)-1-((S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl)-3-methyl-1-oxobutan-2-yl)-3-hydroxycyclopentanecarboxamide 
• 946594-19-0 BMS-457 
• 1443512-83-1 C₂₄H₃₆ClN₃O₃ 
• 1443512-82-0 C₂₄H₃₆ClN₃O₃ 
• 946590-77-8 C₂₅H₃₀ClFN₂O₄ 
• 946588-46-1 C₂₄H₃₆ClN₃O₃ 

Relevant articles and documents

CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.

The discovery of BMS-457, a potent and selective CCR1 antagonist

A series of compounds which exhibited good human CCR1 binding and functional potency was modified resulting in the discovery of a novel series of high affinity, functionally potent antagonists of the CCR1 receptor. Issues of PXR activity, ion-channel pote

PRODRUGS OF A PIPERIDINYL DERIVATIVE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The present application describes prodrugs of the compound of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well a

NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS

The present invention relates to novel morpholine, oxazapane and piperidine derivatives that act as ligands for CC chemokine receptors, such as CCR1. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.

PIPERIDINYL DERIVATIVE AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY

The present application describes the compound of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune

Chemokine receptor antagonists and methods of use thereof

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: formula (1) or physiologically acceptable salt thereof.

CCR1 antagonists and methods of use therefor

The invention provides compounds having the formula: wherein R1 is halogen. The invention also provides compositions comprising the compounds, and methods of treating diseases or disorders that comprise administering one or more of the compound

Chemokine receptor anagonists and methods of use therefor

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.